HMG-CoA Reductase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
|OLDID=1159684 | |OLDID=1159684 | ||
}} | }} | ||
<StructureSection load='1dq8' size='450' side='right' scene='HMG-CoA_Reductase/1dq8_starting_scene/1' caption='Crystal Structure of HMG-CoA, [[1dq8]])'> | <StructureSection load='1dq8' size='450' side='right' scene='HMG-CoA_Reductase/1dq8_starting_scene/1' caption='Crystal Structure of HMG-CoA, [[1dq8]])'>[[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductase''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman">PMID:1374417</ref> It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world. See also [[Ephrin Type-A Receptor]] and [[Neurodevelopmental Disorders]]. | ||
[[HMG-CoA Reductase]] (or '''3-hydroxy-3-methyl-glutaryl-CoA reductase''' or '''HMGR''') is the rate-controlling enzyme of the mevalonate pathway, responsible for cholesterol and other isoprenoid biosynthesis. HMGR is a transmembrane protein, containing 8 domains, that is anchored in the membrane of the endoplasmic reticulum.<ref name="Roitelman">PMID:1374417</ref> It is the major target of the Statins, a cholesterol lowering drug class and the best selling pharmaceutical drugs in the world. See also [[Ephrin Type-A Receptor]] and [[Neurodevelopmental Disorders]]. | |||
[[Image: HMG-CoA_reductase_pathway.png|250px|left|thumb| Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway]] The 1985 Nobel Prize in Physiology or Medicine was awarded to Michael S. Brown and Joseph L. Goldstein, “for their discoveries concerning the regulation of cholesterol metabolism.” Their work on HMGR and LDL elucidated the regulatory complexity of cholesterol synthesis.<ref>http://nobelprize.org/nobel_prizes/medicine/laureates/1985/</ref> | [[Image: HMG-CoA_reductase_pathway.png|250px|left|thumb| Mevalonate Pathway. Note the early stage at which the statins interfere in the pathway]] The 1985 Nobel Prize in Physiology or Medicine was awarded to Michael S. Brown and Joseph L. Goldstein, “for their discoveries concerning the regulation of cholesterol metabolism.” Their work on HMGR and LDL elucidated the regulatory complexity of cholesterol synthesis.<ref>http://nobelprize.org/nobel_prizes/medicine/laureates/1985/</ref> | ||
<br /> | <br /> | ||
